THREAD and Almac Clinical Technologies have entered a strategic collaboration to combine their respective technology platforms to lower the risk of clinical trial delays.
The integrated platforms will enable the companies to provide a range of tools to sponsors and contract research organisations. The aim is to facilitate trials that are more efficient and yield improved outcomes.
THREAD customers will have access to Almac’s IXRS solution and randomisation and trial supply management services as part of the collaboration.
Meanwhile, Almac customers will be able to leverage THREAD’s decentralised clinical trial (DCT) solution.
Almac Clinical Technologies global business development vice-president George Tiger said: “As part of our growing Partnership and Alliance programme, this specific partnership will enable us to offer an additional level of support to Almac clients as they seek to decentralise their clinical trials.”
THREAD and Almac will use single sign-on and application programme interfaces (APIs) to merge their technologies and allow automatic DCT workflows on their platforms.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
The move will reduce duplicate data entry, especially for research sites, and offer integrated reports on trial status to sponsors. It will also maintain automation for operational efficiency.
THREAD CEO John Reites said: “A common pain point for research sites is the abundance of technologies they have to independently maintain for each clinical trial.
“By integrating Almac within our comprehensive platform, sites and study teams will have a single DCT study experience.”
In March, THREAD partnered with Lokavant to provide advanced analytics and actionable insights to businesses that operate DCTs.
Separately, trial technology provider Castor has launched a participant enrolment and eConsent platform to boost access to patients and decrease enrolment timelines.
The platform can enrol patients via a web portal, pre-screen them based on trial criteria, enable remote or onsite consent and then randomise and gather study data using the company’s Clinical Data Management Platform (EDC/CDMS).